awmsg logo



telotristat ethyl (Xermelo®)


Reference No. 2037


Appraisal information

telotristat ethyl (Xermelo®) 250 mg film-coated tablet


Company: Ipsen Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 13/06/2018
AWMSG meeting date: 18/07/2018
   
   
Submission Type: Full Submission
Status: In progress
Advice No: Not available
Ratification by Welsh Government: Not available

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

Indication

Treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy